CO6351710A2 - Composicion topica para el tratamiento de queratosis actinica - Google Patents

Composicion topica para el tratamiento de queratosis actinica

Info

Publication number
CO6351710A2
CO6351710A2 CO11013458A CO11013458A CO6351710A2 CO 6351710 A2 CO6351710 A2 CO 6351710A2 CO 11013458 A CO11013458 A CO 11013458A CO 11013458 A CO11013458 A CO 11013458A CO 6351710 A2 CO6351710 A2 CO 6351710A2
Authority
CO
Colombia
Prior art keywords
mixtures
group
treatment
topical composition
actinic keratosis
Prior art date
Application number
CO11013458A
Other languages
English (en)
Inventor
Manfred Melzer
Carmen Matthies
Klaus Treudler
Christoph Willers
Henning Mallwitz
Original Assignee
Almirall Hermal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40039993&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6351710(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Almirall Hermal Gmbh filed Critical Almirall Hermal Gmbh
Publication of CO6351710A2 publication Critical patent/CO6351710A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/196—Carboxylic acids, e.g. valproic acid having an amino group the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/60—Salicylic acid; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/12—Keratolytics, e.g. wart or anti-corn preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención se refiere a una composición de gel tópica que comprende un agente activo seleccionado del grupo que consiste de inhibidores de ciclooxigenasa, moduladores inmunológicos tópicos, antimetabolitos y mezclas de los mismos; un agente queratolíticamente activo seleccionado del grupo que consiste de agonistas del receptor retinoide, urea, ácidos orgánicos y mezclas de los mismos; un formador de gel que se selecciona del grupo que consiste de homopolímeros y copolímeros de vinilo, derivados de celulosa y mezclas de los mismos; un solvente orgánico que se selecciona del grupo que consiste de alcoholes-C1-C10, ésteres de alcoholes-C1-C10 con ácidos carboxílicos-C1-C10 y mezclas de los mismos y un mejorador de la penetración de la piel.
CO11013458A 2008-07-07 2011-02-07 Composicion topica para el tratamiento de queratosis actinica CO6351710A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP08012237A EP2143421A1 (en) 2008-07-07 2008-07-07 Topical composition for the treatment of actinic keratosis

Publications (1)

Publication Number Publication Date
CO6351710A2 true CO6351710A2 (es) 2011-12-20

Family

ID=40039993

Family Applications (1)

Application Number Title Priority Date Filing Date
CO11013458A CO6351710A2 (es) 2008-07-07 2011-02-07 Composicion topica para el tratamiento de queratosis actinica

Country Status (32)

Country Link
US (1) US8569320B2 (es)
EP (2) EP2143421A1 (es)
JP (2) JP5654987B2 (es)
KR (1) KR101689898B1 (es)
CN (2) CN104825384A (es)
AR (1) AR072685A1 (es)
AU (1) AU2009267471B2 (es)
BR (1) BRPI0915439B8 (es)
CA (1) CA2729974A1 (es)
CL (1) CL2010001642A1 (es)
CO (1) CO6351710A2 (es)
CY (1) CY1116111T1 (es)
DK (1) DK2315581T3 (es)
EA (1) EA019533B1 (es)
EC (1) ECSP11010762A (es)
ES (1) ES2532948T3 (es)
HK (1) HK1154793A1 (es)
HR (1) HRP20150222T1 (es)
IL (1) IL210134A (es)
ME (1) ME02147B (es)
MX (1) MX2011000054A (es)
MY (1) MY158428A (es)
NZ (1) NZ590288A (es)
PE (1) PE20110330A1 (es)
PL (1) PL2315581T3 (es)
PT (1) PT2315581E (es)
RS (1) RS53887B1 (es)
SI (1) SI2315581T1 (es)
TW (1) TWI433692B (es)
UA (1) UA101044C2 (es)
WO (1) WO2010003568A1 (es)
ZA (1) ZA201100653B (es)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5798561B2 (ja) * 2009-10-08 2015-10-21 エムエスディー コンシューマー ケア， インコーポレイテッド 低エーテル組成物およびデリバリー装置
JP5950528B2 (ja) * 2011-09-30 2016-07-13 小林製薬株式会社 皮膜形成性外用製剤
WO2013088375A1 (en) * 2011-12-12 2013-06-20 Leo Laboratories Limited A topical composition comprising an ingenol derivative and an oily solvent
NZ606177A (en) * 2012-01-30 2014-03-28 Dolorgiet Gmbh & Co Kg Compositions for the treatment of actinic keratosis
GB201222405D0 (en) * 2012-12-12 2013-01-23 Leo Lab Ltd Gel compositions
JP2017521470A (ja) * 2014-07-31 2017-08-03 サン ファーマシューティカル インダストリーズ リミテッドＳｕｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌ Ｉｎｄｕｓｔｒｉｅｓ Ｌｔｄ． イソトレチノインの経口医薬組成物
MX2017003251A (es) 2014-09-12 2017-12-20 Antibiotx Aps Uso antibacteriano de salicilanilidas halogenadas.
GB201509326D0 (en) 2015-05-29 2015-07-15 Antibio Tx Aps Novel use
JP6659735B2 (ja) * 2015-07-10 2020-03-04 インフェクトファーム・アルツナイミッテル・ウント・コンシリウム・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 日光角化症の治療における水酸化カリウムの使用
GB201604484D0 (en) 2016-03-16 2016-04-27 Antibiotx Aps And Københavns Uni University Of Copenhagen Topical antibacterial compositions
CA3055938A1 (en) 2017-03-10 2018-09-13 Athenex, Inc. Methods of treating and/or preventing actinic keratosis
US11419834B2 (en) 2019-02-25 2022-08-23 Rhode Island Hospital Methods for treating diseases or infections caused by or associated with H. pylori using a halogenated salicylanilide
US20220175769A1 (en) * 2020-12-08 2022-06-09 Ankh Life Sciences Limited Method of treatment of actinic keratoses
DK202370132A1 (en) * 2023-03-14 2024-10-10 Repoceuticals Aps Compositions for use in the treatment of actinic keratosis

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2802005A (en) 1957-08-06 S-eluorourace
US4234599A (en) * 1978-10-04 1980-11-18 Scott Eugene J Van Treatment of skin keratoses with α-hydroxy acids and related compounds
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
US5167649A (en) * 1988-08-22 1992-12-01 Zook Gerald P Drug delivery system for the removal of dermal lesions
US5093360A (en) * 1989-04-07 1992-03-03 Yu Ruey J Retinal, derivatives and their therapeutic use
GB9023701D0 (en) * 1990-10-31 1990-12-12 Efamol Holdings Medical treatment
JP3117502B2 (ja) * 1991-08-27 2000-12-18 株式会社資生堂 皮膚外用剤
US5627187A (en) 1995-04-12 1997-05-06 Katz; Bruce E. 5-FU for treating actinic kerotoses
KR20000022054A (ko) * 1996-06-20 2000-04-25 아타나스 라비다스 여드름의 국소 치료 제형 및 이의 제조방법
US5993787A (en) * 1996-09-13 1999-11-30 Johnson & Johnson Consumer Products, Inc. Composition base for topical therapeutic and cosmetic preparations
US5955097A (en) * 1996-10-18 1999-09-21 Virotex Corporation Pharmaceutical preparation applicable to mucosal surfaces and body tissues
US6462071B1 (en) * 2000-03-02 2002-10-08 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
ES2223277B1 (es) * 2003-06-19 2006-03-01 Fernando Bouffard Fita Composicion anestesica para administracion topica.
MXPA06002163A (es) * 2003-08-25 2006-05-22 Foamix Ltd Espuma farmaceutica de penetracion.
US20050137164A1 (en) * 2003-09-22 2005-06-23 Moshe Arkin Diclofenac compositions for the treatment of skin disorders
JP5324091B2 (ja) * 2004-06-24 2013-10-23 アイデックス ラボラトリーズ，インコーポレイティド 薬物送達のための医薬組成物及びそれを使用する症状の治療又は予防法
US20070053984A1 (en) 2005-03-03 2007-03-08 Monique Spann-Wade Topical gels compositions
WO2006134406A1 (en) * 2005-06-14 2006-12-21 Uni-Pharma Kleon Tsetis Pharmaceutical Laboratories S.A. Stable pharmaceutical gel of diclofenac sodium
US7851431B2 (en) * 2005-07-27 2010-12-14 Prescription Dispensing Laboratories Treatment of actinic keratoses with calcium channel blockers
US20070264317A1 (en) * 2006-05-15 2007-11-15 Perrigo Israel Pharmaceuticals Ltd. Imiquimod cream formulation
WO2008047857A1 (fr) * 2006-10-18 2008-04-24 Fujifilm Corporation Procédé de production d'une composition comprenant un composé difficilement soluble dans l'eau incorporé dans une matrice hydrophile et préparation pour une utilisation externe comprenant un agent ou médicament anticancéreux ayant un coefficient de partage octanol/eau (log p) de -3,0 ou plus mais pas plus de 3,0, incorporé

Also Published As

Publication number Publication date
CY1116111T1 (el) 2017-02-08
CN104825384A (zh) 2015-08-12
BRPI0915439B1 (pt) 2019-10-08
EP2143421A1 (en) 2010-01-13
ZA201100653B (en) 2011-10-26
EA201100020A1 (ru) 2011-06-30
US20110301130A1 (en) 2011-12-08
ECSP11010762A (es) 2012-03-30
RS53887B1 (en) 2015-08-31
US8569320B2 (en) 2013-10-29
MX2011000054A (es) 2011-11-04
PE20110330A1 (es) 2011-06-11
PT2315581E (pt) 2015-04-02
JP5654987B2 (ja) 2015-01-14
JP2015038129A (ja) 2015-02-26
NZ590288A (en) 2012-08-31
HRP20150222T1 (hr) 2015-05-22
TW201006507A (en) 2010-02-16
AU2009267471B2 (en) 2014-06-05
AR072685A1 (es) 2010-09-15
IL210134A (en) 2015-06-30
MY158428A (en) 2016-10-14
CA2729974A1 (en) 2010-01-14
SI2315581T1 (sl) 2015-05-29
KR20110027838A (ko) 2011-03-16
ME02147B (me) 2015-10-20
EP2315581A1 (en) 2011-05-04
IL210134A0 (en) 2011-02-28
BRPI0915439A2 (pt) 2015-11-10
CL2010001642A1 (es) 2011-04-08
EP2315581B1 (en) 2014-12-17
WO2010003568A1 (en) 2010-01-14
ES2532948T3 (es) 2015-04-06
UA101044C2 (ru) 2013-02-25
KR101689898B1 (ko) 2016-12-26
AU2009267471A1 (en) 2010-01-14
BRPI0915439B8 (pt) 2021-05-25
EA019533B1 (ru) 2014-04-30
DK2315581T3 (en) 2015-03-23
HK1154793A1 (en) 2012-05-04
PL2315581T3 (pl) 2015-06-30
WO2010003568A8 (en) 2011-02-03
JP2011526934A (ja) 2011-10-20
CN102088957A (zh) 2011-06-08
TWI433692B (zh) 2014-04-11

Similar Documents

Publication Publication Date Title
CO6351710A2 (es) Composicion topica para el tratamiento de queratosis actinica
CY1120888T1 (el) Διαδερμικες φαρμακευτικες συνθεσεις περιλαμβανοντας ενεργους παραγοντες
CL2015002710A1 (es) Composiciones de arni contra el componente c5 del complemento y métodos para su uso.
CO7240372A2 (es) Formulaciones farmacéuticas tópicas no acuosas
BR112015019657A2 (pt) composições tópicas e métodos de uso das mesmas
PE20160665A1 (es) Derivados 11-hidroxilo de acidos biliares y conjugados de aminoacidos de los mismos como moduladores del receptor de farnesoid x
CL2012002317A1 (es) Compuestos derivados de tienopirimidinas, inhibitores de quinasas mnk1/mnk2; composicion farmaceutica; y su uso para elt ratamiento o profilaxis de enfermedades metabolicas, tales como diabetes, daño renal, cancer, enfermedades inflamatorias, entre otras.
PE20140489A1 (es) Produccion de un trasplante a partir de dermis animal con disolucion de sulfuro de sodio
PE20131341A1 (es) Combinaciones de agonistas del receptor beta-3-adrenergico y antagonistas del receptor muscarinico para tratar vejiga hiperactiva
CL2013001579A1 (es) Uso de una composicion farmaceutica que comprende un compuesto agonista ep4 para tratar marcas de la piel tales como heridas superficiales, cicatrices o arrugas.
BR112013000613A2 (pt) composições secas e dispositivos que contêm tais composições secas
CY1123805T1 (el) Διαδερμικο σκευασμα που περιεχει αναστολεις cox
GB2525835A (en) Composition comprising a diindolymethane and a retinoid to treat a skin condition
CL2016001130A1 (es) Composiciones sólidas de triglicéridos y usos de estas
UA112418C2 (uk) Терапевтичний болезаспокійливий засіб
PE20151300A1 (es) Composicion antifungica topica para el tratamiento de onicomicosis
PE20140035A1 (es) Composicion inyectable que comprende un antiinflamatorio no esteroideo y un antibiotico
CL2015000197A1 (es) Formulaciones de opioides
AR094035A1 (es) Estimulantes del colageno y su uso en el tratamiento de la piel
AR073512A1 (es) Procedimiento de preparacion de 1,6:2,3-dianhidro - beta d- manopiranosa
CL2010000752A1 (es) Composicion farmaceutica que comprende un acido carboxilico saturado, un compuesto anti-hongos y un gel penetrante en la piel; y su uso en el tratamiento de onicomicosis.
RU2012146168A (ru) Способ профилактики стресса при иммобилизации в эксперименте
RU2012146162A (ru) Способ профилактики стресса при иммобилизации в эксперименте
FR2975595B1 (fr) Utilisation de la guanosine comme agent anti-irritant.
RU2012146166A (ru) Способ профилактики поражения слизистой оболочки желудка при иммобилизации в эксперименте

Legal Events

Date Code Title Description
FC Application refused